|
WO2010049753A2
|
|
A protein extraction buffer, a kit comprising it and method of its use
|
|
WO2009072001A2
|
|
Slc9a3r1 directed diagnostics for neoplastic disease
|
|
CA2629013A1
|
|
Method of diagnosing breast cancer using protein markers
|
|
US2007122414A1
|
|
Surface marker-directed cancer therapeutics
|
|
WO2007119111A2
|
|
Tissue diagnostics for ovarian cancer
|
|
US2007122830A1
|
|
Prohibitin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
|
|
WO2007072219A2
|
|
Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
|
|
WO2007072220A2
|
|
Focused microarray and methods of diagnosing cancer
|
|
WO2007057746A2
|
|
Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
|
|
US2006014225A1
|
|
Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
|
US2005026231A1
|
|
Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
|
CA2509987A1
|
|
Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
|
AU2003302986A1
|
|
Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
|
CA2512513A1
|
|
Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
|
EP1695089A1
|
|
Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
|
US2004259112A1
|
|
Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
|
